

13th November 2020

To,
Manager - DSC
BSE Limited,
Floor 25, P J Towers,
Dalal Street, Mumbai – 400 001

Subject: Outcome of Board Meeting held on 13th November, 2020

Ref.: Scrip Code: 536456. Scrip ID: RJBIOTECH

Dear Sir,

As required under Regulation 33 and all other applicable regulations, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find attached herewith the Standalone Audited Financial Results for the Half Year ended on 30th September, 2020 of the Company.

The meeting of Board of Directors Commenced at 4.00 p.m and concluded at 6.15 p.m.

Kindly take the same on record and acknowledge the receipt.


Thanking You,

Yours Truly,

For R J BIO-TECH LIMITED

Harshna

Harshna Saxena
(Company Secretary)





Office : 1st Floor, Tapadia Terraces, Adalat Road, Aurangabad -05
(0240) (O) 2333140, 2328467, 2363165 (Fax)0240-2363165 (R) 2327520 (M) 97640 90999, 98220 73563
E-Mail :- backoffice@smbco.in, nbangad@gmail.com


INDEPENDENT AUDITOR'S REPORT

To,
The Board of Directors of
R J Bio-Tech Limited.
"Siddharth Arcade", Opp. Holiday Camp, Station Road,
Aurangabad - 431 005

- 1 We have audited the Half Yearly financial results of R J Bio-Tech Limited ("The Company")(Formerly known as R J Bio-Tech Private Limited) for the Half Year ended as on 30.09.2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These Half Yearly financial results, have been prepared on the basis of the Half Yearly financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such Half Yearly financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Half Yearly Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.
- 2 We have conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
- 3 **Basis for Qualified Opinion**
 - i) Following events or conditions indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern and therefore, it may be unable to realise its assets and discharge its liabilities in the normal course of business. The financial statements (and notes thereto) do not disclose this fact. However, the financial statements of the Company have been prepared on a going concern basis.

We draw attention to the standalone financial statements, which indicates that -

- The Company has incurred a net loss of Rs. 15.16 Crores during the half year ended 30th September, 2020 and also its current liabilities over current assets exceeded by Rs. 38.24 Crores
- The Company has accumulated losses and its Net Worth has been fully eroded.
- The Company's financing arrangements expired and the amount outstanding of Rs. 36.89 Crores was payable on September 30, 2020. The Company has been unable to re-negotiate or obtain replacement financing and is currently classified by bank as Non Performing Assets.



- ii) Under the Micro, Small & Medium Enterprises Development Act, 2006 which came into force from 2nd October, 2006, certain disclosures are required to be made relating to Micro, Small & Medium Enterprises. According to the information & explanation given to us and on the basis of our examination of the records of the company, the company has sent necessary communication to all the vendors to confirm their MSME Status, however the same confirmation is awaited. Since the relevant information is not readily available, no disclosure have been made in the accounts.
- iii) The company has not determined the liability towards retirement benefits, such as leave encashment, etc. as per the Accounting Standard 15 - "Employee Benefits" prescribed under section 133 of the Companies Act, 2013. No provision has been made in the books of accounts for the above liability as per the actuarial valuation report. The financial statement do not disclose the financial impact of the above provisions. The Profit in the statement of Profit & Loss and Current Liabilities are understated / overstated to that extent. This constitutes a departure from the Accounting Standard -15 "Employee Benefits".

As a result of the matters stated in Para (i), Para (ii) and Para (iii) above, we were unable to determine whether any adjustments might have been found necessary in respect of recorded assets and liabilities in the Balance Sheet and the corresponding elements making up the Statement of Profit and Loss and Cash Flow Statement.

4 Qualified Opinion


In our opinion and to the best of our information and according to the explanations given to us, except for the effects / possible effects of the matters described in Basis for Qualified Opinion Paragraph above, the statements

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ; and
(ii) Gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of **Net Loss** and other financial information of the company for the period ended 30.09.2020.

- 5 The Statement includes the results for the Half Year ended 30.09.2020 being the balancing figure between the audited results in respect of the full financial year and the published year to date figures upto the half year of the current financial year which were subject to limited review by us.

For S. M. BANGAD & Co.
CHARTERED ACCOUNTANTS


Firm Reg. No. 100974W



[CA NITIN S BANGAD]

PARTNER. M. NO. 49693

UDIN :20049693AAAAEH2149



Date : 13.11.2020
Place :- Aurangabad

R J BIO-TECH LIMITED
CIN : L24234MH2005PLC158420
Audited Statement of Assets and Liabilities as on 30th September, 2020


Particulars	(Rs. in Lakhs)	
	As on 30-09-2020	As on 31-03-2020
	Audited	Audited
I] EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	946.76	946.76
(b) Reserves & Surplus	(5,012.76)	(3,496.82)
(c) Money received against share warrants		-
Total Shareholders Fund	(4,066.00)	(2,550.06)
(2) Share Application money pending allotment		
(3) Deferred Government Grants		
(4) Minority Interest		
(5) Non-Current Liabilities		
(a) Long-term Borrowings	396.85	519.85
(b) Deffered Tax Liabilities (Net)	-	-
(c) Other Long term Liabilities	69.40	67.40
(d) Long-term Provisions	-	-
Total Non-Current Liabilities	466.25	587.25
(6) Current Liabilities		
(a) Short-Term Borrowings	3,617.25	3,617.25
(b) Trade Payables		
i) Micro enterprises and small enterprises	-	-
ii) Other than Micro enterprises and small enterprises	217.04	290.20
(c) Other Current Liabilities	336.37	504.15
(d) Short-Term Provisions	-	92.70
Total Current Liabilities	4,170.66	4,504.29
TOTAL	570.91	2,541.49
II] ASSETS		
(1) Non Current Assets		
(a) Property, Plant and Equipment		
(i) Tangible Assets	174.91	172.28
(ii) Intangible Assets	0.01	0.01
(iii) Capital Work-in-progress	-	-
(iv) Intangible Assets under Development	-	-
Total Property, Plant and Equipment	174.92	172.29
(b) Non-Current Investments	-	-
(c) Deffered tax Assets (Net)	-	-
(d) Long-term loans & Advances	10.85	10.85
(e) Other non-Current assets	38.49	148.41
Total Non-Current Asset	224.26	331.55
(2) Current Assets		
(a) Current Investments	-	-
(b) Inventories	175.60	1,424.12
(c) Trade Receivables	124.94	736.95
(d) Cash & Cash equivalents	9.18	(0.24)
(e) Short-term loans and advances	34.55	45.96
(f) Other current assets	2.39	3.14
Total Current Asset	346.65	2,209.94
TOTAL	570.91	2,541.49

Note:

01. The Audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13.11.2020
02. There were no Investor Complaints received / pending as on 30/09/2020.
03. The Company does not have more than one reportable primary segment in terms of Accounting Standard 17 (AS 17 - Segment Reporting) issued by ICAI/Company (Accounting Standards) Rules, 2006. Therefore, the Company is not required to submit separate segment wise report.
04. Figures of the previous year have been re-grouped / re-arranged wherever considered necessary.

For & on Behalf of the Board of Directors of

R J BIO-TECH LIMITED



(Signature)

(Aditi Joshi)

Director

DIN No.: 05168412

Place: Aurangabad


Date : 13.11.2020

R J BIO-TECH LIMITED
CIN : L24234MH2005PLC158420

Statement of Audited Financial Results for the Half Year ended 30th September 2020

(Rs. in Lakhs)

Sr. No.	Particulars	Half Year Ended	Preceding Half year ended	Corresponding Half year ended	Year to date figure for Current Period ended	Year to date figures for the previous year ended	Previous year ended
		30.09.2020	31.03.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
		Audited	Audited	Unaudited	Audited	Unaudited	Audited
I	Revenue from Operations	1,353.48	283.05	1,055.29	1,353.48	1,055.29	1,338.34
II	Other Operating Income	-	10.50	0.94	-	0.94	11.44
III	Total Revenue (I+II)	1,353.48	293.55	1,056.23	1,353.48	1,056.23	1,349.78
IV	Expenditure						
a.	Cost of material consumed (Refer Note No. 2)	1,046.30	(151.12)	668.95	1,046.30	668.95	517.83
b.	Purchase of stock in trade	-	-	-	-	-	-
c.	Change in inventories of finished goods, work in progress and stock in trade (Refer Note No. 3)	326.47	286.98	(183.50)	326.47	(183.50)	103.48
d.	Employee benefit expenses	77.16	112.12	94.49	77.16	94.69	206.81
e.	Finance cost	0.16	(170.87)	249.34	0.16	249.37	78.47
f.	Depreciation and amortization expenses	4.52	4.90	4.79	4.52	4.79	9.69
g.	Other expenses - (Refer Note No. 4)	1,117.89	233.80	624.66	1,117.89	624.63	858.46
	Total Expenses IV	2,572.49	315.81	1,458.93	2,572.49	1,458.93	1,774.74
V	Profit/(loss) before Exceptional Items or tax (III - IV)	(1,219.01)	(22.26)	(402.70)	(1,219.01)	(402.70)	(424.96)
VI	Exceptional Items	(296.93)	(0.00)	9.34	(296.93)	9.34	9.34
VII	Profit/(loss) before tax (V-VI)	(1,515.94)	(22.27)	(393.36)	(1,515.94)	(393.36)	(415.63)
VIII	Tax Expenses	-	-	-	-	-	-
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	(1,515.94)	(22.27)	(393.36)	(1,515.94)	(393.36)	(415.63)
X	Profit/(loss) from discontinuing operations	-	-	-	-	-	-



XI	Tax expense for discontinued operation	-	-	-	-	-	-
XII	Profit/(loss) from discontinued operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(1,515.94)	(22.27)	(393.36)	(1,515.94)	(393.36)	(415.63)
	Other comprehensive income	-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items	-	-	-	-	-	-
	B (i) that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Items that will be reclassified to profit or loss income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Comprehensive Income for the period (XIII+XIV) (Comprising	-	-	-	-	-	-
XIV.	Profit (Loss) and other comprehensive income for the period)						
XV.	Earnings per equity share (for continuing operation):						
	(1) Basic	(16.01)	(9.55)	(4.15)	(16.01)	(4.15)	(4.39)
	(2) Diluted						
XVI.	Earnings per equity share (for discontinued operation):						
	(1) Basic						
	(2) Diluted						
XVII.	Earnings per equity share (for discontinued and continuing operations						
	(1) Basic	(16.01)	(9.55)	(4.15)	(16.01)	(4.15)	(4.39)
	(2) Diluted						

For & on Behalf of the Board of Directors of
R J BIO-TECH LIMITED



Aditi Joshi

(Aditi Joshi)
Director

DIN No.: 05168412

Place: Aurangabad

Date : 13.11.2020

Registered Office : Siddharth Arcade, Railway Station Road, Aurangabad - 431 005. (M.S.) India Tel. : +91-240-02354912 to 17 Fax : +91-240-2332111
E-mail : info@rjbiotech.com www.rjbiotech.com CIN No. : L24234MH2005PLC158420.

R J BIO-TECH LIMITED
(CIN : L24234MH2005PLC158420)
"Siddharth Arcade", Opp. Holiday Camp, Station Road, Aurangabad - 431 005
Cash Flow Statement For the period ended 30th Sep, 2020

(Rs. In Lakhs)

Sr No.	Particulars	As on 30.09.2020 (Audited)	As on 30.09.2019 (Unaudited)
A)	CASH INFLOW FROM OPERATING ACTIVITIES		
	Profit before tax	(1,219.01)	(393.36)
	Adjustments to reconcile profit before tax to cash provided by operating activities		
	Depreciation and amortisation expense	4.52	4.79
	Interest & Finance Cost	0.16	249.37
	R & D Exp W/off	136.19	31.25
	Effects of Exceptional Items - Expired & Discarded Stock	(296.93)	-
	Deferred Expenses written off	-	-
	Operating Profit Before Working Capital Changes	(1,375.08)	(107.96)
	Adjusted for:		
	Changes in Inventories	-	24.62
	Changes in Trade Receivables	-	(431.71)
	Changes in Loans and advances and other assets	-	25.85
	Changes in Other Current Assets	-	-
	Changes in Liabilities & Provisions	-	(6.60)
	Cash Generated From Operations	(1,375.08)	(495.80)
	Direct Tax Paid	-	-
	NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES	(1,375.08)	(495.80)
B)	CASH FLOWS FROM INVESTING ACTIVITIES		
	Payment towards capital expenditure	(7.15)	(3.53)
	Sale of Property , Plant & Equipments	-	-
	Payment towards Research & Development & other deferred expenses	(26.27)	(47.78)
	Payment towards long-term loans and advances	-	-
	NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES	(33.42)	(51.31)
C)	CASH FLOWS FROM FINANCING ACTIVITIES		
	Repayment of Long Term Borrowings & Long Term Liabilities	-	(12.41)
	Proceeds from short-term borrowings	-	438.74
	Interest & Financial Charges	(0.16)	(249.37)
	NET CASH PROVIDED BY/(USED IN) FINANCING ACTIVITIES	(0.16)	177.35
	NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	9.41	(369.75)
	CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	(0.24)	3.74
	CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	9.17	(366.01)

This is the cashflow statement referred to in our report of even date.

